<ns1:RDF xmlns:ns6="http://prismstandard.org/namespaces/basic/2.0/" xmlns:ns5="http://prismstandard.org/namespaces/pmi/1.0/" xmlns:ns8="http://purl.org/swan/pav/provenance/" xmlns:ns7="http://www.elsevier.com/xml/schema/rdf/common/Metadata-1/" xmlns:ns2="http://purl.org/dc/terms/" xmlns:ns1="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ns4="http://www.elsevier.com/xml/schema/rdf/BasicAssetMetadata-1/" xmlns:ns3="http://www.elsevier.com/xml/schema/rdf/LDR-Satellites/Base-1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:base="http://data.elsevier.com/metadata/BAM-1/pii:S2376999817300417" xsi:schemaLocation="http://www.elsevier.com/xml/schema/rdf/BasicAssetMetadata-1/ http://www.elsevier.com/xml/schema/rdf/BasicAssetMetadata-1/BasicAssetMetadata-1.xsd"><ns3:Satellite ns1:about="http://data.elsevier.com/metadata/BAM-1/pii:S2376999817300417"><ns3:describesResource ns1:resource="http://vtw.elsevier.com/content/pii/S2376999817300417"/><ns3:describesResource ns1:resource="http://api.elsevier.com/content/article/DOI:10.1016/j.clinms.2017.10.002"/><ns3:describesResource ns1:resource="http://api.elsevier.com/content/article/PII:S2376-9998(17)30041-7"/><ns3:satellite-type ns1:resource="http://data.elsevier.com/namespaces/LDR-Satellites/BasicAssetMetadata-1/"/><ns8:createdBy ns1:resource="http://data.elsevier.com/enh-service/LDR-VTW-INT"/><ns8:createdOn>2018-11-30T08:24:07.439Z</ns8:createdOn><ns3:project ns1:resource="http://data.elsevier.com/enh-project/VTW"/></ns3:Satellite><ns1:Description ns1:about="http://data.elsevier.com/metadata/BAM-1/pii:S2376999817300417"><ns2:title>Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots</ns2:title><ns2:isPartOf ns1:resource="http://vtw.elsevier.com/content/pii/S2376999817X00056"/><ns2:creator>Josef Dib</ns2:creator><ns2:creator>Laura Tretzel</ns2:creator><ns2:creator>Andreas Lagojda</ns2:creator><ns2:creator>Dirk Kuehne</ns2:creator><ns2:creator>Wilhelm Schänzer</ns2:creator><ns2:creator>Mario Thevis</ns2:creator><ns2:date>2017-10-28</ns2:date><ns2:created>2017-07-27T00:00:00Z</ns2:created><ns2:modified>2017-10-27T00:00:00Z</ns2:modified><ns2:publisher>Elsevier B.V.</ns2:publisher><ns2:language>en</ns2:language><ns2:type ns1:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1.1"/><ns2:abstract>Abstract AdipoRon and 112254 represent two known synthetic adiponectin receptor (adipoR) agonists. Although AdipoRon is the more potent compound, both have physiological properties that are similar to adiponectin - an adipokine with antidiabetic and antiatherogenic effects. Several transcriptional regulators are activated by adipoR-agonists leading to increased mitochondrial DNA content in vitro , an effect that can be abused by athletes for performance enhancing purposes. In the context of preventive anti-doping research, detection of AdipoRon and 112254 in routine doping control specimens would be valuable. Here, we describe our process for incorporating AdipoRon and 112254 into routine doping control methods involving urine and dried blood spot (DBS) analysis. Method validation including evaluation of specificity, limit of detection, identification capability, carryover, matrix interference, recovery, interday and intraday precision and linearity to standards provided by WADA. For identification in human urine, a liquid chromatography-tandem mass spectrometry-based testing approach was implemented for both adipoR agonists and two respective phase-I metabolites. Recovery of 85–104%, satisfactory limits of detection (i.e., 0.5–1 ng/mL), and imprecision values over three days at three concentration levels of &amp;lt;19% demonstrated the assay’s fitness-for-purpose. For identification from DBS a liquid chromatography-high-resolution/high-accuracy tandem mass spectrometry with online solid-phase extraction was implemented for AdipoRon and 112254. Here also, acceptable recoveries (i.e., 22–33%), limits of detection of 5–10 ng/mL, and imprecision values over three days at three concentration levels of &amp;lt;23%, were demonstrated. Hence, two methods for doping control screening from urine and DBS were established and shown to be fit-for-purpose for routine use.</ns2:abstract><ns4:year>2017</ns4:year><ns4:subtype ns1:resource="http://data.elsevier.com/vocabulary/ElsevierPubItemTypes/FLA"/><ns6:copyright>The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL)</ns6:copyright><ns6:publicationName>Clinical Mass Spectrometry</ns6:publicationName><ns6:issn>2376-9998</ns6:issn><ns6:aggregationType ns1:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1"/><ns6:coverDate>2017-12-01</ns6:coverDate><ns6:coverDisplayDate>December 2017</ns6:coverDisplayDate><ns6:volume>6</ns6:volume><ns6:pageRange>13–20</ns6:pageRange><ns6:startingPage>13</ns6:startingPage><ns6:endingPage>20</ns6:endingPage><ns6:keyword>Sport</ns6:keyword><ns6:keyword>Adipor agonists</ns6:keyword><ns6:keyword>Doping</ns6:keyword><ns6:keyword>Exercise mimetic</ns6:keyword><ns6:keyword>AdipoRon</ns6:keyword><ns6:keyword>Mass spectrometry</ns6:keyword><ns4:orderedCreatorList><ns1:Seq><ns1:li>Josef Dib</ns1:li><ns1:li>Laura Tretzel</ns1:li><ns1:li>Andreas Lagojda</ns1:li><ns1:li>Dirk Kuehne</ns1:li><ns1:li>Wilhelm Schänzer</ns1:li><ns1:li>Mario Thevis</ns1:li></ns1:Seq></ns4:orderedCreatorList><ns2:description>AdipoRon and 112254 represent two known synthetic adiponectin receptor (adipoR) agonists. Although AdipoRon is the more potent compound, both have physiological properties that are similar to adiponec…</ns2:description><ns6:channel ns1:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1.1.1"/><ns7:identifier>pii:S2376999817300417</ns7:identifier><ns2:identifier ns1:resource="CLINMS_2017_36"/><ns4:formattedPII>S2376-9998(17)30041-7</ns4:formattedPII><ns6:doi>10.1016/j.clinms.2017.10.002</ns6:doi><ns4:publicationTimeStart>2017-12-01T00:00:00Z</ns4:publicationTimeStart><ns4:publicationTimeEnd>2017-12-31T23:59:59Z</ns4:publicationTimeEnd></ns1:Description></ns1:RDF>